Tobramycin inhalation powder
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Aeruginosa
Conditions
Pseudomonas Aeruginosa, Cystic Fibrosis
Trial Timeline
Aug 12, 2009 → Oct 6, 2011
NCT ID
NCT00982930About Tobramycin inhalation powder
Tobramycin inhalation powder is a phase 3 stage product being developed by Novartis for Pseudomonas Aeruginosa. The current trial status is completed. This product is registered under clinical trial identifier NCT00982930. Target conditions include Pseudomonas Aeruginosa, Cystic Fibrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02015663 | Approved | Terminated |
| NCT01069705 | Phase 3 | Completed |
| NCT00982930 | Phase 3 | Completed |
| NCT00125346 | Phase 3 | Terminated |
Competing Products
8 competing products in Pseudomonas Aeruginosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| tobramycin + tobramycin | Novartis | Phase 3 | 77 |
| TIS or TIP | Novartis | Approved | 85 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 30 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 74 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 20 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 60 |